Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390574 | 0.81 | KCNQ3 (0.51) | RAB9ANPC1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16533843 | 0.80 | KMT2A (0.46) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29610510 | 0.79 | CXCR2 (0.40) | RAB9ANPC1ALDH1A1PDGFRBKDR | |
| SCHEMBL24312279 | 0.79 | CXCR2 (0.40) | RAB9ANPC1ALDH1A1PDGFRBKDR | |
| SCHEMBL15937424 | 0.79 | PLG (0.42) | RAB9ANPC1PTGDR2F2F10 | |
| SCHEMBL12797362 | 0.78 | ALDH1A1 (0.43) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4053413 | 0.78 | GAA (0.48) | LMNAGAA | |
| SCHEMBL13197996 | 0.77 | NPC1 (0.57) | RAB9ANPC1ALDH1A1KDM4EPOLB | |
| SCHEMBL3228174 | 0.75 | CXCR2 (0.55) | RAB9ANPC1SMN1; SMN2KMT2ACXCR2 | |
| SCHEMBL18989163 | 0.75 | LIPE (0.38) | RAB9ANPC1POLBSMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093765-A1 | NOVEL COMPOUNDS | CALLAHAN JAMES F | 2010-04-15 | — | — | US | disclosed |
| US-20100093766-A1 | NOVEL COMPOUNDS | CALLAHAN JAMES F | 2010-04-15 | — | — | US | disclosed |
| US-7674789-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090239846-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | US | disclosed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093766-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | RAB9A 1510/4885NPC1 1584/4885PTGDR2 2630/4885 |
| US-20090239846-A1 | Novel Compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | RAB9A 1510/4885NPC1 1584/4885PTGDR2 2630/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | RAB9A 1510/4885NPC1 1584/4885PTGDR2 2630/4885 |
| US-20100093765-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | RAB9A 1510/4885NPC1 1584/4885PTGDR2 2630/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | RAB9A 1510/4885NPC1 1584/4885PTGDR2 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.